title: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
abstract: An elevation in circulating serum uric acid is strongly associated with the development of hypertension and renal disease, but whether uric acid has a causal role or whether it simply indicates patients at risk for these complications remains controversial. We tested the hypothesis that uric acid may have a causal role in the development of hypertension and renal disease by examining the effects of mild hyperuricemia in rats. Mild hyperuricemia was induced in rats by providing a uricase inhibitor (oxonic acid) in the diet. Hyperuricemic rats developed elevated blood pressure after 3 weeks, whereas control rats remained normotensive. The development of hypertension was prevented by concurrent treatment with either a xanthine oxidase inhibitor (allopurinol) or a uricosuric agent (benziodarone), both of which lowered uric acid levels. Blood pressure could also be lowered by reducing uric acid levels with either allopurinol or oxonic acid withdrawal. A direct relationship was found between blood pressure and uric acid (r=0.75, n=69), with a 10-mm Hg blood pressure increase for each 0.03-mmol/L (0.5-mg/dL) incremental rise in serum uric acid. The kidneys were devoid of urate crystals and were normal by light microscopy. However, immunohistochemical stains documented an ischemic type of injury with collagen deposition, macrophage infiltration, and an increase in tubular expression of osteopontin. Hyperuricemic rats also exhibited an increase in juxtaglomerular renin and a decrease in macula densa neuronal NO synthase. Both the renal injury and hypertension were reduced by treatment with enalapril or L-arginine. In conclusion, mild hyperuricemia causes hypertension and renal injury in the rat via a crystal-independent mechanism, with stimulation of the renin-angiotensin system and inhibition of neuronal NO synthase.
authors.affiliation: Division of Nephrology, University of Washington Medical Center, Seattle, USA. m_mazzali@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Mazzali
authors.forename: J
authors.initials: J
authors.lastname: Hughes
authors.forename: Y G
authors.initials: YG
authors.lastname: Kim
authors.forename: J A
authors.initials: JA
authors.lastname: Jefferson
authors.forename: D H
authors.initials: DH
authors.lastname: Kang
authors.forename: K L
authors.initials: KL
authors.lastname: Gordon
authors.forename: H Y
authors.initials: HY
authors.lastname: Lan
authors.forename: S
authors.initials: S
authors.lastname: Kivlighn
authors.forename: R J
authors.initials: RJ
authors.lastname: Johnson
mesh_terms: D000818:Animals; D001794:Blood Pressure; D003460:Crystallization; D005355:Fibrosis; D006977:Hypertension, Renal / Q000209:etiology* / Q000503:physiopathology; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D008297:Male; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052248:Nitric Oxide Synthase Type I; D051381:Rats; D017207:Rats, Sprague-Dawley; D012084:Renin-Angiotensin System; D014511:Uremia / Q000097:blood / Q000150:complications* / Q000473:pathology; D014527:Uric Acid / Q000097:blood*
chemical_list: D014527:Uric Acid; D019001:Nitric Oxide Synthase; D052248:Nitric Oxide Synthase Type I; C496322:Nos1 protein, rat